TY - JOUR
T1 - Successful Treatment of Human Waldenström's Macroglobulinemia with Combination Biological and Chemotherapy Agents
AU - Mohammad, Ramzi M.
AU - Al-Katib, Ayad
AU - Pettit, George
AU - Sensenbrenner, Lyle L.
PY - 1994/1
Y1 - 1994/1
N2 - The immunomodulating effects and antitumor activity of two biological agents, bryostatin 1 (Bryol) and α-interferon, were tested in vitro and in vivo either alone or prior to chemotherapy agents, against a Waldenstrom's macroglobulinemia tumor line (WSU-WM). Bryol caused a decrease in the expression of CD10, CD19, IgM, LeulO, and CD22 and a temporary growth inhibition as measured by cell cycle analysis. α-Interferon did not show any major effects. In vivo, severe combined immunodeficient mice were used to test the activity of the agents against WSU-WM. Bryol (i.p.) was given either alone or sequentially with doxorubicin (i.v.), vincristine (i.v.), melphalan (i.v.), and α-interferon (i.v.). Bryol given 24 h before vincristine or melphalan resulted in the highest tumor growth inhibition, tumor growth delay, and tumor cell kill. Two of five mice receiving Bryol/vincristine combination were free of tumors >200 days after treatment and were considered cured. In light of our findings, we recommend that Bryol be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease. Whether Bryol is acting as a differentiating agent or as a direct anti-Waldenstrom's macroglobulinemia tumor agent, remains unclear.
AB - The immunomodulating effects and antitumor activity of two biological agents, bryostatin 1 (Bryol) and α-interferon, were tested in vitro and in vivo either alone or prior to chemotherapy agents, against a Waldenstrom's macroglobulinemia tumor line (WSU-WM). Bryol caused a decrease in the expression of CD10, CD19, IgM, LeulO, and CD22 and a temporary growth inhibition as measured by cell cycle analysis. α-Interferon did not show any major effects. In vivo, severe combined immunodeficient mice were used to test the activity of the agents against WSU-WM. Bryol (i.p.) was given either alone or sequentially with doxorubicin (i.v.), vincristine (i.v.), melphalan (i.v.), and α-interferon (i.v.). Bryol given 24 h before vincristine or melphalan resulted in the highest tumor growth inhibition, tumor growth delay, and tumor cell kill. Two of five mice receiving Bryol/vincristine combination were free of tumors >200 days after treatment and were considered cured. In light of our findings, we recommend that Bryol be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease. Whether Bryol is acting as a differentiating agent or as a direct anti-Waldenstrom's macroglobulinemia tumor agent, remains unclear.
UR - http://www.scopus.com/inward/record.url?scp=0028089047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028089047&partnerID=8YFLogxK
M3 - Article
C2 - 8261437
AN - SCOPUS:0028089047
SN - 0008-5472
VL - 54
SP - 165
EP - 168
JO - Cancer Research
JF - Cancer Research
IS - 1
ER -